Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD79B mutation
i
Other names:
CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
974
Related biomarkers:
Expression
Mutation
‹
›
Associations
(5)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111-218) (NCT05068440)
Phase 2
BeiGene
BeiGene
Recruiting
Phase 2
BeiGene
Recruiting
Last update posted :
05/07/2024
Initiation :
08/11/2021
Primary completion :
12/30/2024
Completion :
12/30/2024
CD79B
|
CD79B mutation • CD79B mutation
|
Brukinsa (zanubrutinib)
ZR-CHOP in DLBCL With Specific Gene Abnormality (NCT05290337)
Phase 2
Fudan University
Fudan University
Recruiting
Phase 2
Fudan University
Recruiting
Last update posted :
03/22/2022
Initiation :
01/04/2022
Primary completion :
01/04/2024
Completion :
01/04/2026
TP53 • MYC • MYD88 • CD79B
|
TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626)
Phase 2
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences
Not yet recruiting
Phase 2
Chinese Academy of Medical Sciences
Not yet recruiting
Last update posted :
08/06/2021
Initiation :
10/01/2021
Primary completion :
04/01/2022
Completion :
07/01/2025
CD20 • MYD88 • CD79B • CD79A
|
CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • Rituxan (rituximab)
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM) (NCT04183569)
Phase N/A
University Hospital, Bordeaux
University Hospital, Bordeaux
Unknown status
Phase N/A
University Hospital, Bordeaux
Unknown status
Last update posted :
04/29/2020
Initiation :
02/19/2019
Primary completion :
05/01/2020
Completion :
05/01/2020
BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
|
CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login